Experience of micropulse cyclophotocoagulation for treatment patients with early stages of glaucoma

Aim to evaluate the efficacy and safety of micropulse transscleral cyclophotocoagulation (MP-TSCPC) modality in patients with early stages glaucoma.
 Material methods. We examined 38 stage primary open-angle uncompensated glaucoma (POAG) (17 stage, 18 advanced stage) before during 12 months after MP-TSCPC treatment (SUPRA device 810, Quantel Medical, France) using modified laser parameters - power W=2000 MW, 31.3 % exposure cycle, total time 4 sectors 200 s, energy 125 J. Fluence 121.8 J/m.
 Results. There were no complications procedure. In all patients, BCVA did not change observation period. A decrease IOP was achieved patients. 6 follow-up, level remained stable averaged 15.5 4.5 mm Hd. Up hypotensive effect persisted up 31% initial IOP, which 16.0 3.5 Hg. As a result, persistent helped reduce number IOP-lowering medications general, cancel them cases 17 Conclusion. protocol showed high efficiency (up value year) reducing intraocular pressure glaucoma. The use visual acuity demonstrated good profile due areactive postoperative Further monitoring is necessary develop practical recommendations for indications regimens.